Safety Monitoring of Omaveloxolone in Friedreich Ataxia: Results from One Year of Clinical Treatment
Abstract Introduction Omaveloxolone, the only approved medication for Friedreich ataxia (FRDA), is an NRF2 activator available since July 2023. We examined safety monitoring of omaveloxolone administration over the first 12 months of administration. Methods We recorded baseline and follow-up serum t...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Adis, Springer Healthcare
2025-04-01
|
| Seri Bilgileri: | Neurology and Therapy |
| Konular: | |
| Online Erişim: | https://doi.org/10.1007/s40120-025-00749-3 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|